UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Pediatric mania and second-generation antipsychotics: Efficacy, administration, and side effects

Author
David Axelson, MD
Section Editor
David Brent, MD
Deputy Editor
David Solomon, MD

INTRODUCTION

For children and adolescents with mania, second-generation antipsychotics are often efficacious and thus frequently prescribed. As an example, a nationally representative survey of outpatient visits for bipolar disorder in the United States between 2005 and 2009 found that in adolescents, antipsychotics were prescribed in 29 percent of the visits [1]. In younger children, antipsychotics were prescribed in 12 percent of the visits.

This topic reviews the efficacy, administration, and side effects of second-generation antipsychotics in youth with mania. Other aspects of pediatric bipolar disorder are discussed separately, including an overview of choosing treatment; general principles of using pharmacotherapy; the efficacy and core elements of adjunctive psychotherapy; assessment and diagnosis; and the epidemiology, clinical features, and course of illness:

(See "Pediatric bipolar disorder: Overview of choosing treatment".)

(See "Pediatric bipolar disorder and pharmacotherapy: General principles".)

(See "Pediatric bipolar disorder: Efficacy and core elements of adjunctive psychotherapy".)

                

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Mon Apr 25 00:00:00 GMT 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Olfson M, Blanco C, Liu SM, et al. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry 2012; 69:1247.
  2. Findling RL, Nyilas M, Forbes RA, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2009; 70:1441.
  3. Tramontina S, Zeni CP, Ketzer CR, et al. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry 2009; 70:756.
  4. Findling RL, Kauffman R, Sallee FR, et al. An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder. J Child Adolesc Psychopharmacol 2009; 19:431.
  5. Thomas T, Kuich KW, Findling RL. Bipolar disorders. In: Clinical Manual of Child and Adolescent Psychopharmacology, Second Edition, McVoy M, Findling RL. (Eds), American Psychiatric Publishing, Washington, DC 2013. p.227.
  6. NICE: National Institute for Health and Care Excellence. Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder. July 2013. http://www.nice.org.uk/guidance/TA292 (Accessed on December 04, 2014).
  7. Findling RL, Correll CU, Nyilas M, et al. Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. Bipolar Disord 2013; 15:138.
  8. Findling RL, Landbloom RL, Szegedi A, et al. Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar I Disorder. J Am Acad Child Adolesc Psychiatry 2015; 54:1032.
  9. Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007; 164:1547.
  10. Olsen BT, Ganocy SJ, Bitter SM, et al. Health-related quality of life as measured by the child health questionnaire in adolescents with bipolar disorder treated with olanzapine. Compr Psychiatry 2012; 53:1000.
  11. McCormack PL. Olanzapine: in adolescents with schizophrenia or bipolar I disorder. CNS Drugs 2010; 24:443.
  12. Wozniak J, Mick E, Waxmonsky J, et al. Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. J Child Adolesc Psychopharmacol 2009; 19:539.
  13. Kryzhanovskaya LA, Xu W, Millen BA, et al. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine. J Child Adolesc Psychopharmacol 2012; 22:157.
  14. Joshi G, Petty C, Wozniak J, et al. A prospective open-label trial of paliperidone monotherapy for the treatment of bipolar spectrum disorders in children and adolescents. Psychopharmacology (Berl) 2013; 227:449.
  15. Pathak S, Findling RL, Earley WR, et al. Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial. J Clin Psychiatry 2013; 74:e100.
  16. DelBello MP, Kowatch RA, Adler CM, et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006; 45:305.
  17. Scheffer RE, Tripathi A, Kirkpatrick FG, Schultz T. Rapid quetiapine loading in youths with bipolar disorder. J Child Adolesc Psychopharmacol 2010; 20:441.
  18. Haas M, Delbello MP, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2009; 11:687.
  19. Pavuluri MN, Henry DB, Findling RL, et al. Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder. Bipolar Disord 2010; 12:593.
  20. Geller B, Luby JL, Joshi P, et al. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry 2012; 69:515.
  21. Salpekar JA, Joshi PT, Axelson DA, et al. Depression and Suicidality Outcomes in the Treatment of Early Age Mania Study. J Am Acad Child Adolesc Psychiatry 2015; 54:999.
  22. Walkup JT, Wagner KD, Miller L, et al. Treatment of Early-Age Mania: Outcomes for Partial and Nonresponders to Initial Treatment. J Am Acad Child Adolesc Psychiatry 2015; 54:1008.
  23. Fu-I L, Boarati MA, Stravogiannis A, Wang YP. Use of risperidone long-acting injection to support treatment adherence and mood stabilization in pediatric bipolar patients: a case series. J Clin Psychiatry 2009; 70:604.
  24. Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 2008; 69 Suppl 4:26.
  25. Findling RL, Cavuş I, Pappadopulos E, et al. Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2013; 23:545.
  26. Jensen KG, Juul K, Fink-Jensen A, et al. Corrected QT changes during antipsychotic treatment of children and adolescents: A systematic review and meta-analysis of clinical trials. J Am Acad Child Adolesc Psychiatry 2014.
  27. Correll CU, Lops JD, Figen V, et al. QT interval duration and dispersion in children and adolescents treated with ziprasidone. J Clin Psychiatry 2011; 72:854.
  28. Thomas T, Stansifer L, Findling RL. Psychopharmacology of pediatric bipolar disorders in children and adolescents. Pediatr Clin North Am 2011; 58:173.
  29. Masi G, Mucci M, Millepiedi S. Clozapine in adolescent inpatients with acute mania. J Child Adolesc Psychopharmacol 2002; 12:93.
  30. Kowatch RA, Suppes T, Gilfillan SK, et al. Clozapine treatment of children and adolescents with bipolar disorder and schizophrenia: A clinical case series. J Child Adolesc Psychopharmacol 1995; 5:241.
  31. Kowatch RA, Fristad M, Birmaher B, et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005; 44:213.
  32. Pfeifer JC, Kowatch RA, DelBello MP. Pharmacotherapy of bipolar disorder in children and adolescents: recent progress. CNS Drugs 2010; 24:575.
  33. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302:1765.
  34. Varley CK, McClellan J. Implications of marked weight gain associated with atypical antipsychotic medications in children and adolescents. JAMA 2009; 302:1811.
  35. Seida JC, Schouten JR, Boylan K, et al. Antipsychotics for children and young adults: a comparative effectiveness review. Pediatrics 2012; 129:e771.
  36. Arango C, Giráldez M, Merchán-Naranjo J, et al. Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients. J Am Acad Child Adolesc Psychiatry 2014; 53:1179.
  37. Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet 2016; 387:1561.
  38. McClellan J, Kowatch R, Findling RL, Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:107.
  39. NICE National Institute for Health and Care Excellence. Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. September 2014. http://www.nice.org.uk/guidance/CG185 (Accessed on November 18, 2014).
  40. Andrade SE, Lo JC, Roblin D, et al. Antipsychotic medication use among children and risk of diabetes mellitus. Pediatrics 2011; 128:1135.
  41. Nielsen RE, Laursen MF, Vernal DL, et al. Risk of diabetes in children and adolescents exposed to antipsychotics: a nationwide 12-year case-control study. J Am Acad Child Adolesc Psychiatry 2014; 53:971.
  42. Shain BN, COMMITTEE ON ADOLESCENCE. Collaborative role of the pediatrician in the diagnosis and management of bipolar disorder in adolescents. Pediatrics 2012; 130:e1725.
  43. Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry 2008; 69:1157.
  44. Correll CU, Kane JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol 2007; 17:647.